Shanghai JMT-Bio Inc.

6 in Phase 3

Quick facts

HB1801 · Oncology
HB1801 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses.
JMT101 injection · Immunology
JMT101 injection is a monoclonal antibody targeting a specific protein to modulate the immune system.
JMT103 · Diabetes
JMT103 is a small molecule that targets the SGLT2 receptor.
KN026 · Oncology
KN026 is a bispecific antibody that simultaneously binds to HER2 and HER3 receptors to block their signaling pathways in cancer cells.
Osimertinib tablet · Oncology
Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations, blocking downstream signaling in cancer cells.
SG001 · Diabetes
SG001 is a small molecule drug that targets the SGLT2 receptor.

Cyclosporin Capsules · Immunology
Cyclosporin Capsules inhibit calcineurin, preventing T-cell activation and proliferation.
JMT601

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Shanghai JMT-Bio Inc. has 6 drugs in Phase 3, 2 in Phase 2, 5 in Phase 1. Late-stage candidates include HB1801, JMT101 injection, JMT103, KN026.